Skip to main content
Premium Trial:

Request an Annual Quote

CAT Calls to Chambre, but What About Celera?

Premium

For better or worse, Peter Chambre is bound to be under scrutiny as the new CEO of Cambridge Antibody Technology in Melbourne, UK. When Chambre, 46, bowed out of his COO post at Celera, it was with the explanation that he wasn’t the right person to lead the genomics company down the road to its biopharmaceutical future.

Then, a few months later, he wound up at CAT, announcing that he would guide the company in its “transition to a product-focused biopharmaceutical company.” Chambre avoids questions about the obvious comparison of positions, but says, “It’s a difficult transition to make [to biopharmaceuticals], and yet the starting point for CAT is one that few others have.” The company, he contends, has “the strongest clinical pipeline of human monoclonal antibodies.” It also has the beginnings of a target pipeline, with its own and shared leads — one partner Chambre mentions is Genzyme. “That doesn’t make the transition easy, but it does make it more possible,” he says.

Chambre joined Celera in 2000 — “the phase of Celera’s growth which involved taking the company from the point at which it had raised substantial amounts of cash, but it was clear that the information business was not going to provide the kind of returns” it needed. Chambre played a large role in setting a path for the company, insisting that it had to become a biopharmaceutical player. He also advocated establishing the company’s proteomics platform and was key to the acquisition of Axys Pharmaceuticals.

Formerly the CEO of UK drug discovery company Bespak, Chambre also spent six years in management consulting. He’s taken the first several weeks at CAT to meet as many of the 270 employees as possible and to get to know the company’s products, which sell primarily to big pharma. “I’m not deeply embedded in the science or the research of the company,” he says. So he focuses more on identifying future opportunities for the company: “You can’t stand still in this field.”

— Meredith Salisbury

 

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.